NDC 49884-160 – Everolimus
Everolimus .75 mg/1 · Tablet · Oral
Product NDC49884-160
Product details
- Brand name
- Everolimus
- Generic name
- Everolimus
- Labeler
- Par Health USA, LLC
- Dosage form
- Tablet
- Route
- Oral
- Marketing category
- ANDA · ANDA205775
- Marketed since
- December 16, 2022
- Listing expires
- December 31, 2026
- Pharmacologic class
- Kinase Inhibitor; mTOR Inhibitor Immunosuppressant
Active ingredients
- Everolimus .75 mg/1
Package NDC codes (1)
| Package NDC | Description | Since |
|---|---|---|
| 49884-160-02 | 6 BLISTER PACK in 1 CARTON (49884-160-02) / 10 TABLET in 1 BLISTER PACK (49884-160-52) | Dec 16, 2022 |
Other Everolimus products
- 67877-718 Everolimus .25 mg/1 · Tablet · Ascend Laboratories, LLC
- 67877-719 Everolimus .5 mg/1 · Tablet · Ascend Laboratories, LLC
- 67877-721 Everolimus 1 mg/1 · Tablet · Ascend Laboratories, LLC
- 67877-720 Everolimus .75 mg/1 · Tablet · Ascend Laboratories, LLC
- 59651-933 Everolimus .75 mg/1 · Tablet · Aurobindo Pharma Limited
- 59651-931 Everolimus .25 mg/1 · Tablet · Aurobindo Pharma Limited
- 59651-934 Everolimus 1 mg/1 · Tablet · Aurobindo Pharma Limited
- 59651-932 Everolimus .5 mg/1 · Tablet · Aurobindo Pharma Limited
- 70377-012 Everolimus 7.5 mg/1 · Tablet · Biocon Pharma Inc.
- 70377-010 Everolimus 2.5 mg/1 · Tablet · Biocon Pharma Inc.
- 70377-011 Everolimus 5 mg/1 · Tablet · Biocon Pharma Inc.
- 70377-013 Everolimus 10 mg/1 · Tablet · Biocon Pharma Inc.